[Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
Arushanian
E B
EB
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002415:Cats; D002799:Cholinergic Fibers / Q000502:physiology; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology*; D004723:Endorphins / Q000502:physiology; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D051379:Mice; D018377:Neurotransmitter Agents / Q000502:physiology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D017981:Receptors, Neurotransmitter / Q000502:physiology; D012701:Serotonin / Q000502:physiology; D013378:Substantia Nigra / Q000503:physiopathology; D009435:Synaptic Transmission; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D014150:Antipsychotic Agents; D004723:Endorphins; D018377:Neurotransmitter Agents; D017981:Receptors, Neurotransmitter; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D006220:Haloperidol; D004298:Dopamine
O neĭrolepticheskom parkinsonizme i pozdneĭ diskinezii i metodakh farmakologicheskoĭ korrektsii étikh patologicheskikh sostoianiĭ (obzor).